Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemiaAndrea Ghelli Luserna di Rorà, Giovanni Martinelli, Neil Beeharry et al.|Journal of Hematology & Oncology|2018Cited by 56
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemiaAndrea Ghelli Luserna di Rorà, Giovanni Martinelli, Ilaria Iacobucci et al.|Oncotarget|2016Cited by 42
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing PrognosisIlaria Iacobucci, Giovanni Martinelli, Barbara Giannini et al.|Blood|2013Cited by 3
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program ExperienceCristina Papayannidis, Giovanni Martinelli, Stefania Paolini et al.|Blood|2016Cited by 2
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 AlterationsMaria Chiara Fontana, Giovanni Martinelli, Giovanni Marconi et al.|Blood|2016Cited by 2